ProNGF mutants and uses thereof in the production of beta-NGF

Patent metadata

Field	Value
Publication number	US-9617322-B2
Application number	US-201214366460-A
Country	US
Kind code	B2
Filing date	Dec 19, 2012
Priority date	Dec 19, 2011
Publication date	Apr 11, 2017
Grant date	Apr 11, 2017

Abstract

The present invention relates to a proNGF mutant and to uses thereof, in particular the use of a proNGF mutant for producing human beta-NGF. The present invention discloses a method of preparing a biologically active human beta-NGF from an inactive insoluble proNGF mutant. A proNGF mutant of the invention is substituted by any amino acid but not Arg or Lys at the native protease cleavage site R 1 SK 3 R 4 at least at positions R 1 and K 3 corresponding to positions 101 and 103 of the human wildtype proNGF sequence.

First claim

The invention claimed is:

1. A proNGF mutant wherein the protease cleavage site R 1 SK 3 R 4 is substituted at least at positions R 1 K 3 corresponding to positions 101 and 103 of the human wild type proNGF sequence (SEQ ID NO: 1)
wherein the amino acid in position 101 of human wild type proNGF sequence (SEQ ID NO: 1) is substituted by Valine, in position 103 by Alanine, and wherein the amino acid at position 102 is Serine and the amino acid at position 104 is Arginine, or wherein the proNGF mutant comprises the amino acid sequence of SEQ ID NO: 5.

2. The proNGF mutant according to claim 1 , wherein the mutant is obtained by recombinant expression in prokaryotic cells.

3. The proNGF mutant according to claim 1 , wherein the mutant is obtained by recombinant expression in E. coli.

Assignees

• Lorey Susan
• Janowski Bernhard
• Pultke Heiko
• Kathmann Daniela
• Parthier Antje
• Anton Andreas
• Wacker Chemie Ag

Inventors

• Lorey Susan
• Janowski Bernhard
• Pultke Heiko
• Kathmann Daniela
• Parthier Antje
• Anton Andreas

Classifications

• A61P27/06

  Antiglaucoma agents or miotics · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title